Frazier Lifesciences Acquisition Corporation
Frazier Lifesciences Acquisition Corporation (FLAC) Stock Overview
Explore Frazier Lifesciences Acquisition Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
0
P/E Ratio
17.99
EPS (TTM)
$0.15
ROE
0.07%
FLAC Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Frazier Lifesciences Acquisition Corporation (FLAC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $10.44.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.99 and a market capitalization of 0. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.
Two Union Square, Seattle, WA
2021